CY1108692T1 - Μεθοδος θεραπειας μιας κακοηθειας σε ενα υποκειμενο και φαρμακευτικη συνθεση για χρηση σεαυτη - Google Patents
Μεθοδος θεραπειας μιας κακοηθειας σε ενα υποκειμενο και φαρμακευτικη συνθεση για χρηση σεαυτηInfo
- Publication number
- CY1108692T1 CY1108692T1 CY20091100019T CY091100019T CY1108692T1 CY 1108692 T1 CY1108692 T1 CY 1108692T1 CY 20091100019 T CY20091100019 T CY 20091100019T CY 091100019 T CY091100019 T CY 091100019T CY 1108692 T1 CY1108692 T1 CY 1108692T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mistake
- subject
- treatment
- pharmaceutical composition
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Αποκαλύπτεται μέθοδος θανάτωσης μη κανονικών κυττάρων, όπως κακοηθών κυττάρων που συμπεριλαμβάνουν κύτταρα μελανώματος, χρησιμοποιώντας έναν ιό που αναγνωρίζει τουλάχιστον ένα από ένα μόριο προσκόλλησης κυττάρου και μία ρυθμιστική πρωτεΐνη συμπληρώματος. Ο ιός μπορεί να είναι ένα μέλος της οικογένειας Picornaviridae. Οι ιοί ομάδας Coxsackie Α έχουν βρεθεί ότι είναι ιδιαιτέρως κατάλληλοι. Το μόριο προσκόλλησης κυττάρου επιθυμητά είναι ένα μέλος της υπεροικογένειας ανοσοσφαιρίνης (lg). Τυπικά, η ρυθμιστική πρωτεΐνη συμπληρώματος θα είναι DAF.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ4256A AUPQ425699A0 (en) | 1999-11-25 | 1999-11-25 | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
EP00979268A EP1235590B1 (en) | 1999-11-25 | 2000-11-27 | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108692T1 true CY1108692T1 (el) | 2014-04-09 |
Family
ID=3818400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100019T CY1108692T1 (el) | 1999-11-25 | 2009-01-12 | Μεθοδος θεραπειας μιας κακοηθειας σε ενα υποκειμενο και φαρμακευτικη συνθεση για χρηση σεαυτη |
Country Status (12)
Country | Link |
---|---|
US (5) | US7361354B1 (el) |
EP (2) | EP2016952B1 (el) |
JP (2) | JP5085825B2 (el) |
AT (1) | ATE411814T1 (el) |
AU (1) | AUPQ425699A0 (el) |
CA (1) | CA2422429C (el) |
CY (1) | CY1108692T1 (el) |
DE (1) | DE60040616D1 (el) |
DK (1) | DK1235590T3 (el) |
ES (2) | ES2316394T3 (el) |
PT (1) | PT1235590E (el) |
WO (1) | WO2001037866A1 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
LV12861B (lv) * | 2002-06-14 | 2002-10-20 | Aina Muceniece | Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
JP2007527719A (ja) * | 2004-03-11 | 2007-10-04 | ヴィロターグ ピーティワイ リミテッド | 改変された腫瘍崩壊性ウイルス |
WO2006017914A1 (en) | 2004-08-20 | 2006-02-23 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
ZA200702269B (en) * | 2004-08-20 | 2008-09-25 | Viralytics Ltd | Methods and compositions for treatment of hematologic cancers |
US20080160031A1 (en) * | 2005-01-17 | 2008-07-03 | Viralytics Limited | Method and Composition for Treatment of Neoplasms |
PL2826856T3 (pl) | 2013-07-16 | 2016-06-30 | Sia Latima | Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie |
SG10201801562PA (en) * | 2014-02-27 | 2018-04-27 | Viralytics Ltd | Combination method for treatment of cancer |
US10639337B2 (en) * | 2017-09-29 | 2020-05-05 | Technische Universität Berlin | Method for treating cancer with a Coxsackievirus B3 (CVB3) variant |
CN112641811A (zh) * | 2020-01-20 | 2021-04-13 | 山西高等创新研究院 | 一种抗肿瘤病毒 |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
CN118086228A (zh) * | 2022-11-28 | 2024-05-28 | 厦门大学 | 用于治疗肿瘤的柯萨奇b组1型病毒 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585254A (en) | 1987-08-21 | 1996-12-17 | University Of Colorado Foundation, Inc. | Autonomous parvovirus gene delivery vehicles and expression vectors |
EP0466815A4 (en) | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
US5714374A (en) * | 1990-09-12 | 1998-02-03 | Rutgers University | Chimeric rhinoviruses |
CA2051289C (en) | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
EP0591382A4 (en) | 1991-06-24 | 1995-01-18 | Univ New York | METHOD FOR SYNTHESIS OF NOVO ACELLULAR OF PICORNAVIRUS. |
JPH06509578A (ja) | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
DK0931830T3 (da) | 1993-02-16 | 2001-06-11 | Onyx Pharma Inc | Cytopatiske vira til terapi og profylakse af neoplasi |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
DE69432409T2 (de) | 1993-04-30 | 2003-12-24 | Wellstat Biologics Corp | Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
EP0868498B1 (en) * | 1995-12-22 | 2003-01-22 | Minnesota Mining And Manufacturing Company | Blended pressure-sensitive adhesives |
US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
ES2292207T3 (es) | 1997-10-09 | 2008-03-01 | Wellstat Biologics Corporation | Tratamiento de neoplasmas con virus clonales, sensibles al interferon. |
FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
WO1999028750A1 (en) * | 1997-12-03 | 1999-06-10 | The University Of North Carolina At Chapel Hill | Frnk proteins in the treatment of tumor cells |
EP1061806A4 (en) | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES |
US6060316A (en) | 1998-06-09 | 2000-05-09 | President And Fellows Of Harvard College | Methods of targeting of viral entry |
US6264940B1 (en) | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
DE60039730D1 (de) | 1999-02-05 | 2008-09-11 | Arch Dev Corp | Genetisch manipulierte Herpesviren zur Behandlung von Tumoren |
JP2000279178A (ja) * | 1999-02-24 | 2000-10-10 | Japan Found Cancer Res | ウイルスベクター |
JP2003530301A (ja) | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
AU2005201079C1 (en) | 1999-04-15 | 2008-11-06 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
DE19939095A1 (de) | 1999-08-18 | 2001-02-22 | Univ Eberhard Karls | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
WO2001019380A2 (en) | 1999-09-17 | 2001-03-22 | Pro-Virus, Inc. | Oncolytic virus |
EP1227828A1 (en) | 1999-11-12 | 2002-08-07 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
EP1230378B1 (en) | 1999-11-15 | 2007-06-06 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
AU770517B2 (en) | 1999-11-25 | 2004-02-26 | Viralytics Limited | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AU2004202292B2 (en) | 1999-11-25 | 2007-06-14 | Viralytics Limited | Method of Treating a Malignancy in a Subject |
GB2375113B (en) | 2000-01-21 | 2004-10-20 | Biovex Ltd | A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer |
CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
WO2002043647A2 (en) | 2000-12-01 | 2002-06-06 | University Of Ottawa | Oncolytic virus |
WO2002087625A1 (en) | 2001-05-02 | 2002-11-07 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
EP1387694A2 (en) | 2001-05-09 | 2004-02-11 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
ATE500808T1 (de) | 2001-05-11 | 2011-03-15 | Wellstat Biologics Corp | Onkolytische virustherapie |
CA2352439A1 (en) | 2001-07-17 | 2003-01-17 | Patrick W. K. Lee | Engineering oncolytic viruses |
CA2449013C (en) | 2001-07-23 | 2012-05-22 | Onyx Pharmaceuticals, Inc. | Viral mutants that selectively replicate in targeted human cancer cells |
AU2003216502B2 (en) | 2002-03-01 | 2008-04-10 | Sloan-Kettering Institute For Cancer Research | Prevention of recurrence and metastasis of cancer |
JP2005521398A (ja) | 2002-03-27 | 2005-07-21 | ベイラー カレッジ オブ メディスン | 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス |
WO2003092579A2 (en) | 2002-04-29 | 2003-11-13 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
DE03722131T1 (de) | 2002-05-09 | 2005-09-15 | Oncolytics Biotech, Inc., Calgary | Methode zur schmerzbekämpfung mit onkolytischen viren |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
WO2005002607A2 (en) | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
EP1648233A4 (en) | 2003-07-08 | 2006-08-23 | Univ Arizona | VACCINE VACCINE MUTANTS INSTEAD OF ONCOLYTIC AGENTS |
CA2540177A1 (en) | 2003-09-26 | 2005-04-07 | Novartis Ag | Seneca valley virus based compositions and methods for treating disease |
JP2007527719A (ja) | 2004-03-11 | 2007-10-04 | ヴィロターグ ピーティワイ リミテッド | 改変された腫瘍崩壊性ウイルス |
US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
WO2006047301A2 (en) | 2004-10-21 | 2006-05-04 | The Penn State Research Foundation | Parvovirus methods and compositions for killing neoplastic cells |
-
1999
- 1999-11-25 AU AUPQ4256A patent/AUPQ425699A0/en not_active Abandoned
-
2000
- 2000-11-27 EP EP08018165.4A patent/EP2016952B1/en not_active Expired - Lifetime
- 2000-11-27 US US10/148,008 patent/US7361354B1/en not_active Expired - Lifetime
- 2000-11-27 DE DE60040616T patent/DE60040616D1/de not_active Expired - Lifetime
- 2000-11-27 JP JP2001539480A patent/JP5085825B2/ja not_active Expired - Fee Related
- 2000-11-27 DK DK00979268T patent/DK1235590T3/da active
- 2000-11-27 CA CA2422429A patent/CA2422429C/en not_active Expired - Lifetime
- 2000-11-27 PT PT00979268T patent/PT1235590E/pt unknown
- 2000-11-27 ES ES00979268T patent/ES2316394T3/es not_active Expired - Lifetime
- 2000-11-27 EP EP00979268A patent/EP1235590B1/en not_active Expired - Lifetime
- 2000-11-27 WO PCT/AU2000/001461 patent/WO2001037866A1/en active IP Right Grant
- 2000-11-27 ES ES08018165.4T patent/ES2442000T3/es not_active Expired - Lifetime
- 2000-11-27 AT AT00979268T patent/ATE411814T1/de active
-
2008
- 2008-02-29 US US12/040,813 patent/US8722036B2/en not_active Expired - Fee Related
-
2009
- 2009-01-12 CY CY20091100019T patent/CY1108692T1/el unknown
-
2011
- 2011-05-02 JP JP2011102853A patent/JP2011190266A/ja active Pending
-
2014
- 2014-03-31 US US14/231,528 patent/US20150037287A1/en not_active Abandoned
-
2015
- 2015-09-29 US US14/869,440 patent/US20160250268A1/en not_active Abandoned
-
2017
- 2017-01-13 US US15/406,459 patent/US20170348366A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AUPQ425699A0 (en) | 1999-12-23 |
CA2422429A1 (en) | 2001-05-31 |
US7361354B1 (en) | 2008-04-22 |
EP1235590A1 (en) | 2002-09-04 |
PT1235590E (pt) | 2009-02-02 |
EP2016952A2 (en) | 2009-01-21 |
CA2422429C (en) | 2014-03-11 |
DE60040616D1 (de) | 2008-12-04 |
EP2016952B1 (en) | 2013-12-25 |
US20150037287A1 (en) | 2015-02-05 |
US20160250268A1 (en) | 2016-09-01 |
EP1235590A4 (en) | 2004-12-29 |
DK1235590T3 (da) | 2009-02-23 |
JP5085825B2 (ja) | 2012-11-28 |
ES2442000T3 (es) | 2014-02-07 |
US20090123427A1 (en) | 2009-05-14 |
JP2011190266A (ja) | 2011-09-29 |
ATE411814T1 (de) | 2008-11-15 |
EP2016952A3 (en) | 2010-05-19 |
JP2003514870A (ja) | 2003-04-22 |
ES2316394T3 (es) | 2009-04-16 |
EP1235590B1 (en) | 2008-10-22 |
US20170348366A1 (en) | 2017-12-07 |
WO2001037866A1 (en) | 2001-05-31 |
US8722036B2 (en) | 2014-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108692T1 (el) | Μεθοδος θεραπειας μιας κακοηθειας σε ενα υποκειμενο και φαρμακευτικη συνθεση για χρηση σεαυτη | |
DE69521620T2 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
TR199902124T2 (xx) | �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller. | |
DE59910083D1 (de) | Verwendung von Thiazolidin- oder Pyrrolidinderivaten von Aminosäuren als antihyperglykämische Mittel | |
EA200100502A1 (ru) | СПОСОБЫ И КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ КОНФОРМАЦИОННОЙ СТАБИЛЬНОСТИ БЕЛКА СЕМЕЙСТВА p53 | |
FR2712286B1 (fr) | Nouveaux N-mercaptoalkyl alcanediamines et leur utilisation. | |
DK0526544T3 (da) | Terapeutiske anvendelser af actinbindende forbindelser | |
EA200101250A1 (ru) | Предупреждение и терапия амилоидогенного заболевания | |
DK1301201T3 (da) | Behandling af glycogenosis type II | |
DK15589D0 (da) | Kemiske forbindelser | |
DE69804659D1 (de) | 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss | |
DE3876400D1 (de) | Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen. | |
ATE224714T1 (de) | Behandlung von tinnitus mit neuroprotektiven wirkstoffen | |
DE69635582D1 (de) | Diagnostika und behandlungen von peridontalen erkrankungen | |
DE3785602D1 (de) | Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom. | |
DE69526216T2 (de) | Antifungaleverfahren und mitteln | |
ATE79031T1 (de) | Verwendung von ketonderivaten zur behandlung von depressionen. | |
DE69027472D1 (de) | Arylsubstituierte Rhodaninderivate | |
ATE170847T1 (de) | Verwendung von 5-amino-phthaloylhydrazid als antihypoxisches und defensives mittel | |
DE60332481D1 (de) | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems | |
TR199800801T2 (xx) | Travmatik beyin yaralanmalar�n�n tedavisi. | |
ATE320266T1 (de) | Induktion von antigen-spezifischen t-zellen durch interferon | |
ATE40116T1 (de) | 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva. | |
ATE526992T1 (de) | Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung | |
DE69519219D1 (de) | Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie |